Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes
Status:
Completed
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This study is designed to characterize the safety, steady-state pharmacokinetics (PK) of
IMT-002, and will serve as a dose range identification for the pharmacodynamic effect of
blocking self-antigen presentation in adults with type 1 diabetes (T1D) having the human
leukocyte antigen (HLA)-DQ8 gene.